purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation biib earnings call period ending march image source motley fool biogen biib q earnings callapr etcontents prepared remark question answer call participant prepared remark operatorgood morning name jennifer conference operator today time would like welcome everyone biogen firstquarter earnings call business update operator instruction today conference recorded thank would like turn conference mr chuck triano head investor relation mr triano may begin conferencechuck triano head investor relation thanks jennifer good morning good afternoon good evening everyone welcome biogens firstquarter earnings call begin remind earnings release related financial table including gaap financial measure reconciliation gaap nongaap financial measure discus today investor section biogencom gaap financials provided table table includes reconciliation gaap nongaap financial result believe nongaap financial result better represent ongoing economics business reflect manage business internally also posted slide website used call would point making forwardlooking statement based expectation statement subject certain risk uncertainty actual result may differ materiallyi encourage consult risk factor discussed sec filing additional detail today call joined president chief executive officer chris viehbacher head president north america alisha alaimo cfo mike mcdonnell dr priya singhal head development u available qa session chris alisha mike make opening comment move qa session operator instruction way turn call chris chris viehbacher president chief executive officer thank chuck good morning everybody well certainly great able announce earningspershare growth first quarter first time several year underlying business performance biogen allowed u actually demonstrate earningspershare growth major achievement clearly still got lot work think feel like turning corner company would like actually take opportunity thank biogen colleague instituted awful lot change within company would like thank commitment passion patience throughout process think seeing change occurred number tried bring lot focus discipline really putting resource behind thing good drive value one thing may see awful lot reinvestment going one early boss career told save way prosperity business absolutely true really set fit growth project see number track achieve billion gross saving million net cost saving way million increased cash flow well end really tried redesign organization focused business decade multiple sclerosis franchise launching four firstinclass new medicine really needed make sure supporting launch fact despite cost reduction margin improvement mike going go detail behind hundred million dollar invested new launch overall expense research development decreased focus actually enabled u increase investment asset conviction much costsavings exercise redesign change culture degree let u look new launch obviously one everybody interested leqembi move slide look number different layer obviously first seeing really good quarteronquarter trend seen number patient drug increased two half fold compared finished fourthquarter inmarket revenue almost tripled q versus q last year obviously important thing really important look much business three half decade lost count many launch seen extraordinarily difficult launch really amount change physician facing really profound go around hospital talk doctor talk seeing doctor really becomes evident awful lot challenge getting even first patient treatment one hospital going take took three month get approval hire nurse help navigate system another major medical center develop fiveyear business plan able access infusion bed look uncertainty around pet scan reimbursement although cm clarified lot mac pulled still lot difficulty getting clarity way channel know really encouraged look number although lot challenge lot time investment physician think lot physician credit investing time necessarily getting reimbursed getting done overcoming challenge barrier think important see need look patient accomplished people loved family seeing dreaded disease pull patient away daybyday basis think seeing awful lot momentum think awful lot credit neurologist center overcoming challenge think going allow u continue see quarteronquarter growth may completely linear alisha go detail take time get protocol inplace even get first patient tendency let u handful patient get comfortable system done starting see volume pull one interesting thing launch generally look revenue surrogate demand linkage quite clear taken upfront time see revenue pull think one thing seeing first quarter actually seeing little bit linkage demand revenue behind process place physician ready clearly underlying demand behind think given u lot confidence invest expansion yous field force plan would also say launch really start st september even could argue fully mode able launch pet scan reimbursement cleared yous team eisai biogen done awful lot work look data first seven month launch really looking redeploying resource see important think team really working well together number new element promotional mix start come play progress second quarter biogen point view think early put forecast going looking monthovermonth new patient start increase revenue would certainly say extremely encouraged progress occurred could switch gear another key growth driver skyclarys alisha go detail think also show investor progressing versus analog rare disease market behave typically market always catchup population rare disease take catchup population work system look underlying demand remember patient sitting waiting room huge amount work go finding patient think actually one biogens strength think give confidence continue invest think knowhow within biogen one reason want build rare disease franchise got patient therapy u really significant number also really encouraged launch europe already got remember drug approved end january yet already patient treatment know europe go countrybycountry get reimbursement early access program charge revenue already submitted reimbursement dossier five country u think europe increasingly add revenue probably story think looking acceptance uptake launch also successful start know awful lot patient latin america already submitted brazil example submitting argentina think actually going major benefit opportunity u well remember patient asia genetic disease really affect people european descent fact quite interesting talking key opinion leader germany actually done genetic study basically follow explorer went going find patient think let u dive little bit deeper turn alishaalisha alaimo president biogen u thank chris good morning everyone able join call today alisha alaimo chuck shared lead business north america really unique period biogens history multiple firstinclass drug launch yous give u opportunity drive return growth team also meaningful support people living alzheimers friedreichs ataxia postpartum depression thought might helpful provide perspective market dynamic launch share seeking tailored approach help provide patient access therapy let begin alzheimers market chris mentioned seeing many major health system across country take deliberate staged phased approach meaning setting pathway get patient started diagnosis treatment monitoring believe seeing dynamic idns turning page focusing expanding extending model q saw several idns across region scale patient volume among priority idns unit tripled quarter compared quarter contributed overall estimated patient therapy increasing approximately two half time quarter versus quarter believe acceleration new patient really began emerge end quarter example new patient since launch added march today among priority idns approved leqembi pt process nearly idns approval placed order chris also mentioned seeing physician gain experience leqembi saw number unique prescribers quarter double compared quarter believe still early phase unlocking potential treat high volume patient priority idns thought might helpful share example dynamic site level one large health system midwest added leqembi formulary july last year six month later entering q system ordered unit however end march ordered unit similar example shared also health system southeast added leqembi formulary august five month later entering q system ordered unit end q system ordered unit treat patient context local neurologist network region ordered unit time period perhaps able scale process treat patient however believe wellknown southeast idn planning move beyond flagship side care treat multiple location another example expand extend trend idns believe many system appear completing staging phase think recent trend observed support continued belief leqembi represents significant commercial opportunity mid longer term access infrastructure progressing patient volume accelerating believe also right time expand field force biogen leader working hire customerfacing field team join eisai simultaneously activate patient community biogen eisai launched new directtopatient caregiver omnichannel marketing campaign digital program pointofcare resource focused already diagnosed patient believe care neurologist promising signal emerging lookforward providing update future moving skyclarys believe driving strong performance launch continue exceed market penetration rate rare disease launch analog april patient therapy estimated addressable friedreichs ataxia patient yous achieved market penetration exceeds strong spinraza launch typical rare disease launch believe moving beyond catchup population reach additional patient previously received diagnosis suspected friedreichs ataxia though patient number may uneven anticipate adding patient month last quarter shared integrated sophisticated rare disease capability drive improvement access logistics patient support notably market access team continued make progress securing favorable policy quarter today nearly yous pharmacy life skyclarys reimbursement patient support access effort critical help patient start therapy soon possible remain treatment long term meaningful foundation patient therapy focusing two key area next phase launch first educating community neurologist pcp friedreichs ataxia skyclarys second engaging additional appropriate patient begin focus hcps remember friedreichs ataxia addition patient concentrated top center excellence believe also treated community support physician expanded field footprint using ai analyze data help reach hcps may untreated patient insight relevant site care patient last engaged physician believe help patient even sooner genetic testing anticipate patient confirm potential diagnosis determine skyclarys treatment option far patient activation focus encouraged realworld experience patient sharing social medium experience story help diagnosed patient many story impact skyclarys include report slowing disease progression case even improvement symptom long term addition organic story anticipate launching skyclarys social medium campaign soon believe strong start know people living friedreichs ataxia help look forward supporting brings zurzuvae chris mentioned encouraged performance launch date think seeing several positive trend provider patient experience reimbursement first let begin provider across multiple physician type believe many provider demonstrating urgency treat notably obgyns led overall prescribing quarter believe encouraging often first see ppd patient furthermore breadth adoption continued grow march nearly double number hcps prescribed zurzuvae compared january seen early prescribers require call treat keep mind zurzuvae scheduled product available specialty pharmacy believe psychiatrist generally familiar working specialty pharmacy could new process many obgyns working educate provider step required support appropriate patient second hcps early experience zurzuvae shared patient reported significant improvement depressive symptom within day starting treatment several patient sharing personal day treatment experience platform like tiktok believe courage tell story help educate woman living postpartum depression third believe making good progress government commercial access many payer already policy place majority favorable others continue cover zurzuvae even without formal policy place two three national pharmacy benefit manager providing coverage zurzuvae without overly burdensome restriction active discussion third national pbm await decision medicaid tends take longer almost half state including several largest accelerated review quarter believe unusual process typically take year fda approval encouraged approximately twothirds medicaid life published policy appear minimal access restriction anticipate remaining state review coverage throughout continue support review much possible handing mike want underscore important responsibility help people living alzheimers friedreichs ataxia postpartum depression working urgency help patient community believe making significant progress mission look forward continuing share update would like pas mikemike mcdonnell chief financial officer thank alisha hello everyone would like start highlevel overview financial profile seeing progress context fit growth program maintain sharp focus improving profitability endeavor return company eps growth revenue growth well please note financial comparison make versus first quarter regarding top line four recent launch contributed revenue first quarter offset decline m business noted previous earnings call recent webcast investor conference expect year revenue skewed toward second half year expect due timing shipment spinraza outside yous well expected growth profile recently launched product gross margin saw improvement percentage point quarter revenue mix shifted due increasing highmargin product revenue replacing lowermargin contract manufacturing revenue also million idle capacity charge first quarter none first quarter rd prioritization fit growth initiative clear impact nongaap rd sga expense refer core opex quarter resulted decrease year year saving contributed meaningful growth nongaap operating income year year operating margin quarter compared first quarter encouraging improvement far believe still work done continue improve metric bit color revenue dynamic first quarter total revenue billion decrease actual constant currency m franchise revenue declined approximately driven competition usual channel seasonality see first quarter within m vumerity revenue grew benefited global patient growth well favorable channel dynamic first quarter regarding tecfidera eu seen generic exit market drove exyous growth tecfidera quarter continue believe entitled market protection eu february quick doubleclick rare disease revenue quarter skyclarys delivered million revenue including approximately million europe launch several country underway spinraza yous revenue quarter remain encouraged resilience spinraza revenue outside yous declined majority yearoveryear decline due shipment timing certain emerging market continue generally see stable patient number globally would expect shipping dynamic outside yous largely normalize throughout remainder also saw modest negative impact competition foreign exchange quarter fullyear expect global spinraza revenue decline lowsingledigit percentage zurzuvae delivered million revenue believe inclusive channel stocking anticipation increasing demand common new launch lastly contract manufacturing revenue notably lower year year reflected guidance full year continue expect contribution line significantly lower last year due completing number batch commitment firstquarter nongaap cost sale total revenue improvement percentage point previously mentioned improvement driven favorable product mix revenue new product launch replaced lower margin contract manufacturing revenue also related lower idle capacity charge first quarter firstquarter nongaap rd expense decreased million driven primarily saving achieved fit growth remain track achieve cost saving billion gross million sic million net investment end also saw saving result rd portfolio prioritization meaningful impact discontinued program focused spend area believe higher probability success nongaap sga expense decreased approximately million first quarter primarily due million garelated cost reduction realized connection fit growth program offset increase operational spending sale marketing activity support leqembi skyclarys launch also note prior year included million related termination copromote agreement m project product japan together contributed nongaap operating income growing nongaap operating margin improving nongaap eps growth next brief update balance sheet ended quarter approximately billion debt billion cash marketable security net debt roughly billion march st billion total debt included million billion term loan put place time reata acquisition march st repaid million billion facility remaining million expected repaid second quarter year quarter earlier original expectation end year would note cash marketable security figure include million payment samsung received earlier month continued generate strong free cash flow first quarter approximately million free cash flow overall balance sheet remains strong position increasing capacity invest growth initiative regarding strategic review biosimilars business point received acceptable offer thirdparty process remains ongoing remain disciplined continue explore option including retaining business next would like discus fullyear guidance range assumption reaffirming expectation fullyear nongaap diluted earnings per share reflects expected growth approximately midpoint range compared previous assumption guidance including see slide remain unchanged would like remind potential rd success milestone optin payment associated upcoming clinical data readout made allowance potential payment guidance course whether paid dependent data resulting decision finally announced completion sale one two priority review voucher million point expect earmark proceeds business investment support business development opportunity arise closing remain committed number one goal returning biogen sustainable top bottomline growth creating longterm value shareholder open call questionschuck triano head investor relation thanks mike jennifer go question question answer operatorthank operator instruction first question come line eric schmidt cantor fitzgeralderic schmidt cantor fitzgerald analyst hi thanks much update taking question guess leqembi maybe priya couple update last month ema delay chmp recommendation also know partner eisai announced could submit subcu approval finished immunogenicity study hoping could update u timeline initiative going forward thank youpriya singhal head research development yes thanks eric maybe start saying working eisai really provide patient optionality subcutaneous formulation approach entirely data driven encouraged see bioequivalence met last year shared ctad important milestone thereafter engaged fda currently characterize approaching split strategy subcutaneous formulation first foremost working submit rolling submission subcutaneous autoinjector maintenance going earliest eisai already submitted fasttrack application awaiting soon get make submission continue generate data threemonth immunogenicity fda required second exposure subcutaneous formulation higher iv formulation believe interest patient optimize dose lead convenience optimizing dose something already ongoing currently ongoing year term timeline get fast track subcutaneous maintenance file immediately rolling review expect would year even get fast track completed threemonth immunogenicity data q second subcutaneous induction therapy expect would file first quarter eisai already communicated investor comment early march would also like remind u completed intravenous maintenance filing q aimed thank youchuck triano head investor relation thank operator next question pleaseoperatorwell go next paul matteis stifelpaul matteis stifel financial corp analyst good morning thank taking question wondering could get updated perspective business development relates capacity therapeutic area stage development commercial context kind uncertain promising uncertain trajectory lecanemab influence appetite execute something versus maybe wait bit thank youchris viehbacher president chief executive officer thanks paul think year going focused business development bring new asset early stage research development always called neuroscience company reality neuroscience highrisk area always understand underlying disease biology disease progress slowly lead long expensive trial often proofofconcept study phase remain committed neuroscience personal view think diversified enough company size already last year signaled would like go adjacency rare disease think actually tremendous commercial capability rare disease special commercial requirement need sometimes support diagnosis hurdle payer overcome course finding patient awful lot tool think able immunology immunology company since getgo since m really autoimmune disease think use opportunity licensing collaboration expand think balance sheet something really extraordinary came along suppose look think sit right would thinking anything year acquisition front certainly size mike maybe talk balance sheet capabilitymike mcdonnell chief financial officer yes paul would comment balance sheet good spot look net debt position end first quarter pro forma samsung payment paydown make second quarter term loan billion net debt generate billion ebitda somewhere turn half two turn leverage certainly could add another turn leverage something liked least temporarily generate couple billion dollar free cash flow per year think context maybe billion billion capacity sort number thing might really interested looking something reatalike probably little logical capacity wise beyondchuck triano head investor relation thanks mike chris take next question pleaseoperatoryes go next salveen richter goldman sachssalveen richter goldman sachs analyst good morning thanks taking question skyclarys could speak outlook bolus dynamic impacted specifically talked yous market penetration thinking peak penetration yous expectation pace uptake europe net pricing thank youchris viehbacher president chief executive officer alisha want take yous follow europealisha alaimo president biogen u yes think look yous market penetration probably saw analog slide launch gone well thus far also said made sort catchup population lot really good thing place right launching parallel identify hopefully get rest population way think market though two set patient set highly engaged physician another set engaged probably last two five year enough data analytics understand exactly physician patient moved identifying lot office especially community could patient two might diagnosed general ataxia friedreichs referred earlier call expanding field force footprint targeted approach office order increase market penetration see something like spinraza also performed well also driven quite good market penetration product even though competitor marketplace skyclarys competitor really market expect continue next several year penetrate far go know approximate patient could friedreichs ataxia planning everything get many quickly possiblechuck triano head investor relation thanks alishachris viehbacher president chief executive officer yes europe way singlepayer system actually really ideal rare disease lot patient yous even reimbursement even insurance coverage awful lot hurdle yous healthcare system imposes upon patient lot really see europe think seeing rapid uptake catchup population difference patient treatment revenuegenerating patient first actually commercial launch germany get reimbursement relatively quickly country come online go individual country reimbursement process objective actually build patient number free drug moment eaps eaps charge going little lumpy look revenue line would say extremely encouraged uptake patient exus latin america could well story think may see first launch brazil early part chuck triano head investor relation great thanks chris move next question pleaseoperatoryes go next umer raffat evercoreumer raffat evercore isi analyst hi guy thanks taking question one priya may know latestage lupus readout cd ligand antibody summer also realize time point readout week instead week guess question knowing clear doseresponse efficacy prior trial could speak b cell impact different dos whether prolonged duration could actually help b cell impact upcoming readout thank youpriya singhal head research development thanks umer looked phase study carefully decided included week endpoint bicla phase study ultimately looking meaningful change primary endpoint key secondary endpoint sle severe flare prevention patient achieving low disease activity also think bicla sensitive clinically meaningful composite measure sle disease activity requires disease improvement across body system moderate severe baseline activity without worsening need escalation background medication modified trial refined population think going really important kind look forward readout piece think keep mind considered modify population study get answer really quickly bring potentially dapi patient hope answer questionchuck triano head investor relation thanks priya let u go next question pleaseoperatorwell go next michael yee jefferiesmike yee jefferies analyst hey guy thanks wanted revisit skyclarys comment know said planning add patient monthtomonth talk trajectory skyclarys year relates also offset like discontinuation rate etc etc factor also book germany revenue year talk dynamic revenue skyclarys may sneak one clarification priya said subcu induction filing leqembi q wanted clear said thank muchpriya singhal head research development yes outcome filing period communicate optimize dose go forwardmike yee jefferies analyst ok skyclarysalisha alaimo president biogen u yes skyclarys quite complicated monthtomonth say patient obviously getting via start form say highly engaged population pretty much maxing absolutely know captured physician also going discontinuation rate noted going patient pulled start form putting product course may miss dose two right compliance monthtomonth lumpy say add patient dynamic going patient population outlook year give specific number going continue add every single month able find patient community put take number end day ensure still leading rare disease analog going generate market penetrationchris viehbacher president chief executive officer yes europe booking revenue germany actually actually launched austria czech republic well country actually able charge early access program europe revenue come probably see full eu region revenue certainly revenue contribution certain country europechuck triano head investor relation great thanks chris let u go next question pleaseoperatorwell go next colin bristow ubscolin bristow ubs analyst good morning thanks taking question maybe one leqembi commercial setup one investor concern important feedback hearing physician around le sale marketing presence perhaps expected heard prepared remark saying expect increase yous footprint able sort quantify current yous commercial footprint increase always planned based review current footprint adequate thank youalisha alaimo president biogen u thank much question really take step back look strategically looked launch always said going stepwise approach knew beginning site going take get running wait several indicator cm giving full approval ncd overturned pet said want go gate really huge field force able actually impact penetrate market instead decided went focused approach focused really top account think handle majority diagnosed patient especially neurology care said market get place think ready expansion expand comment physician coming back saying seeing lot sale effort think also really context getting site running take lot effort also want three four five different people going account support focused really getting large idns running center come forward really could move quite quickly got running see expansion take place going focus mainly large idns opening expand extend satellite office going allow larger cohort patient come diagnosis treatment next phase build believe done lot analytics behind lot third party weigh appropriate sizing eisai believe going right footprint drive next acceleration growthchuck triano head investor relation let turn priya clarification back mike yees question subcupriya singhal head research development thank thank wanted clarify outcome fiscal year eisais fiscal year q subcutaneous induction course could range would involve sbla prior potentially priority review aspect could shift eisai communicated wanted reaffirm thank youchuck triano head investor relation outcome filingpriya singhal head research development yeschuck triano head investor relation obviously earlierpriya singhal head research development earlierchuck triano head investor relation yespriya singhal head research development thank youchuck triano head investor relation thanks priya let u move next question pleaseoperatorwell go next brian abraham rbc capital marketsbrian abraham rbc capital market analyst hi good morning thanks much taking question regard leqembi subcu fda request immunogenicity data curious sense drove request level confidence pk linear using half subcu dose proposing patient course treatment transition iv subcu maintenance thankspriya singhal head research development sure thanks brian overall know tested milligram naive patient population clarity ad openlabel extension substudy subcutaneous addition modeling data proposing milligram weekly maintenance fda requiring additional immunogenicity data see reasonable request already process generating overall expect bioequivalence going question really immunogenicity actually generating patient would tested expect remind second aspect questionbrian abraham rbc capital market analyst proposing patient transition iv subcu maintenance data supporting course treatment transition happenpriya singhal head research development yes think important filed intravenous maintenance like already completed filing q really come three line evidence study phase study gaap period modeling well openlabel extension phase informed maintenance iv filing really decided along fda appropriate time transition iv biweekly weekly fourweekly addition following subcutaneous maintenance discussion really systematic need first get iv maintenance parallel sc maintenance hope make sensechuck triano head investor relation thanks priya let u move next question pleaseoperatorwell go next jay olson oppenheimerjay olson oppenheimer company analyst hey thanks providing update seems like compared previous quarter focusing three commercial launch relatively le rd pipeline particular reason shift focus much work plan optimize rd portfolio thank youchris viehbacher president chief executive officer start mean think first four data readout coming midyear think felt would data make sense bring back rd got data would say actually prioritization point view priya weighin think largely done job project either project conviction project waiting data outcome inflight given nature neuroscience project wait need wait see data say think going find u much disciplined whether progress gonogo decision think clearly defined think next job really build pipeline talked earlier want diversify business little bit past priya certainly working along jane thinking thing additionally bring pipeline outside priya know whether want add anything therepriya singhal head research development thanks chris think covered exactly right excited four readout preparing already worked gonogo criterion continue remain excited rest pipeline mid latestage particularly antitau aso biib well two phase program sle litifilimab well dapi talked litifilimab also cutaneous lupus number project early phase development trying disciplined making sure make evidence databased decisionschuck triano head investor relation thanks thanks priya next question pleaseoperatorwell go next chris raymond piper sandlerchris raymond piper sandler analyst thanks maybe strategic question biz dev strategy chris heard comment around diversifying away neurology guy saying deal focused area m actually look across industry decent early innovation m even business decline check still indicate biogen remains trusted company awful lot value would argue market presence guess maybe question strategically activity business development due view need diversify away m strategically view seen early asset worth licensing underlying dynamic m market led guy prioritize area thankschris viehbacher president chief executive officer yes well little bit lot think first abandoned m program research early unmet need m really narrowed really progressive form tough indication really go program still al fact think fact qalsody approved actually proven enormous scientific achievement may major financial achievement really open field biomarker tell whether something working al number program al huntington program parkinson know got tau think tau lupus see program high conviction within company feel think right wellplaced neurology would say m neurology reality sit program difficult predict expensive long running actually look ability external deal field also narrow many people working cns space mean abandoning fact fact go really tough disease really source pride within biogen say continue amazed capability talent within organization reality need predictable result rd think lot capability within company see u ever moving going left turn oncology something like think legitimacy rare disease expanding immunologyand fact think m fact lupus really indicator think going continue branch also branch opportunity set collaboration diversifying portfoliochuck triano head investor relation thanks chris take last question please operatoroperatoryes go next terence flynn morgan stanleyterence flynn morgan stanley analyst great thanks taking question maybe twopart leqembi wondering obviously talked number unique prescribers doubling quarter wondering much breadth expecting field force expansion think forward early insight duration treatment seeing far thank youalisha alaimo president biogen u yes thank question outlook rest year really think phase idns even see small account move fast community really take step back look context idns got approval full approval july took six eight month large system get organized staged phased approach talked fact actually opening site diagnosing prescribing believe going also see number physician prescribing increasing continue increase throughout rest year look many physician targeting number actually prescribing still good delta see continuing especially field force coming covering goal really drive acceleration large idns talked priority keep mind actually target quite keep referring priority many idns also prescribing also expanding extending second part question around chuck triano head investor relation durationalisha alaimo president biogen u duration interesting lot conversation many prescribing site physician lay specific explicit expectation patient go therapy expectation come every two week get iv infusion stay product seen thus far believe happening thus far patient staying product hear feedback physician also hear feedback number see data see far duration plan keeping patient product think question duration absence data physician keeping patient onchuck triano head investor relation right thanks alisha thanks joining u today call ir team course available followup good rest dayoperatoroperator signoff duration minutescall participantschuck triano head investor relationschris viehbacher president chief executive officeralisha alaimo president biogen usmike mcdonnell chief financial officereric schmidt cantor fitzgerald analystpriya singhal head research developmentpaul matteis stifel financial corp analystsalveen richter goldman sachs analystumer raffat evercore isi analystmike yee jefferies analystcolin bristow ubs analystbrian abraham rbc capital market analystjay olson oppenheimer company analystchris raymond piper sandler analystterence flynn morgan stanley analyst biib analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool recommends biogen motley fool disclosure policy